ID   TU-OC-1
AC   CVCL_L700
SY   TUOC1; Tottori University-Ovarian Clear cell-1
DR   cancercelllines; CVCL_L700
DR   Cosmic; 1889261
DR   Cosmic; 2482703
DR   Wikidata; Q54973329
RX   PubMed=23430509;
RX   PubMed=28196595;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Doubling time: 38.4 +- 3.5 hours (PubMed=23430509).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=23430509).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C40078; Ovarian clear cell adenocarcinoma
DI   ORDO; Orphanet_398971; Clear cell adenocarcinoma of the ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   65Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 05-10-23; Version: 15
//
RX   PubMed=23430509; DOI=10.1007/s13577-013-0062-y;
RA   Itamochi H., Kato M., Nishimura M., Oumi N., Oishi T., Shimada M.,
RA   Sato S., Naniwa J., Sato S., Nonaka M., Kudoh A., Terakawa N.,
RA   Kigawa J., Harada T.;
RT   "Establishment and characterization of a novel ovarian clear cell
RT   adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA
RT   gene.";
RL   Hum. Cell 26:121-127(2013).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//